Prime Medicine (PRME) Competitors $2.64 -0.27 (-9.28%) (As of 04:45 PM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsTrends PRME vs. BCRX, NVAX, IMCR, MESO, BLUE, VIR, ADPT, PSTX, IMTX, and LENZShould you be buying Prime Medicine stock or one of its competitors? The main competitors of Prime Medicine include BioCryst Pharmaceuticals (BCRX), Novavax (NVAX), Immunocore (IMCR), Mesoblast (MESO), bluebird bio (BLUE), Vir Biotechnology (VIR), Adaptive Biotechnologies (ADPT), Poseida Therapeutics (PSTX), Immatics (IMTX), and LENZ Therapeutics (LENZ). These companies are all part of the "biological products, except diagnostic" industry. Prime Medicine vs. BioCryst Pharmaceuticals Novavax Immunocore Mesoblast bluebird bio Vir Biotechnology Adaptive Biotechnologies Poseida Therapeutics Immatics LENZ Therapeutics BioCryst Pharmaceuticals (NASDAQ:BCRX) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, earnings, risk, community ranking, dividends, media sentiment, valuation, analyst recommendations and profitability. Which has more risk & volatility, BCRX or PRME? BioCryst Pharmaceuticals has a beta of 1.79, indicating that its share price is 79% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 1.88, indicating that its share price is 88% more volatile than the S&P 500. Do analysts recommend BCRX or PRME? BioCryst Pharmaceuticals presently has a consensus price target of $15.60, indicating a potential upside of 111.67%. Prime Medicine has a consensus price target of $12.67, indicating a potential upside of 369.14%. Given Prime Medicine's stronger consensus rating and higher possible upside, analysts plainly believe Prime Medicine is more favorable than BioCryst Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioCryst Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80Prime Medicine 0 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 3.00 Do institutionals & insiders hold more shares of BCRX or PRME? 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 4.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Comparatively, 23.5% of Prime Medicine shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media favor BCRX or PRME? In the previous week, BioCryst Pharmaceuticals had 1 more articles in the media than Prime Medicine. MarketBeat recorded 3 mentions for BioCryst Pharmaceuticals and 2 mentions for Prime Medicine. BioCryst Pharmaceuticals' average media sentiment score of 1.38 beat Prime Medicine's score of 0.77 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioCryst Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Prime Medicine 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is BCRX or PRME more profitable? Prime Medicine has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -30.01%. BioCryst Pharmaceuticals' return on equity of 0.00% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets BioCryst Pharmaceuticals-30.01% N/A -24.06% Prime Medicine N/A -107.87%-74.97% Does the MarketBeat Community believe in BCRX or PRME? BioCryst Pharmaceuticals received 461 more outperform votes than Prime Medicine when rated by MarketBeat users. However, 68.75% of users gave Prime Medicine an outperform vote while only 66.53% of users gave BioCryst Pharmaceuticals an outperform vote. CompanyUnderperformOutperformBioCryst PharmaceuticalsOutperform Votes48366.53% Underperform Votes24333.47% Prime MedicineOutperform Votes2268.75% Underperform Votes1031.25% Which has higher earnings and valuation, BCRX or PRME? Prime Medicine has lower revenue, but higher earnings than BioCryst Pharmaceuticals. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBioCryst Pharmaceuticals$412.58M3.70-$226.54M-$0.61-12.08Prime Medicine$800K442.67-$198.13M-$2.05-1.32 SummaryPrime Medicine beats BioCryst Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Ad Brownstone ResearchMissed Nvidia? Buy Elon Musk’s “Silent Partner”In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.So please click here to see the details because a lot of people could get rich. Get Prime Medicine News Delivered to You Automatically Sign up to receive the latest news and ratings for PRME and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRME vs. The Competition Export to ExcelMetricPrime MedicineBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$354.14M$2.94B$5.10B$19.48BDividend YieldN/A1.85%4.83%3.51%P/E Ratio-1.3246.72133.9443.10Price / Sales442.67411.221,156.9017.54Price / CashN/A182.1340.5621.73Price / Book1.973.834.845.40Net Income-$198.13M-$42.03M$118.62M$987.88M7 Day Performance-14.56%-5.11%13.62%-3.32%1 Month Performance-15.09%5.78%13.91%-0.39%1 Year Performance-69.70%19.69%33.64%15.14% Prime Medicine Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRMEPrime Medicine3.6622 of 5 stars$2.64-9.3%$12.67+379.8%-67.0%$346.27M$800,000.00-1.29234BCRXBioCryst Pharmaceuticals3.8332 of 5 stars$7.36-2.3%$15.60+112.0%+21.0%$1.52B$412.58M-12.34530Positive NewsNVAXNovavax3.8999 of 5 stars$9.21+1.1%$17.83+93.6%+66.7%$1.48B$847.25M-4.031,543IMCRImmunocore2.625 of 5 stars$29.05+0.5%$65.64+125.9%-54.2%$1.45B$296.31M-30.43497Short Interest ↓MESOMesoblast1.1492 of 5 stars$12.18+3.6%$11.50-5.6%+484.6%$1.39B$5.90M0.0080News CoverageGap UpBLUEbluebird bio2.5787 of 5 stars$6.66+5.0%$49.14+637.9%-86.3%$1.29B$53.12M-3.39323Gap UpVIRVir Biotechnology2.2464 of 5 stars$7.62+2.3%$36.40+377.7%-26.2%$1.05B$86.18M-1.90587ADPTAdaptive Biotechnologies3.584 of 5 stars$6.64+5.4%$6.50-2.1%+33.9%$979.93M$170.28M-4.70709Analyst ForecastPSTXPoseida Therapeutics3.7061 of 5 stars$9.52+0.1%$9.50-0.2%+193.2%$930.77M$64.70M-15.10260IMTXImmatics1.5472 of 5 stars$7.29+1.1%$16.67+128.6%-26.8%$870.11M$115.50M-10.92260Short Interest ↑LENZLENZ Therapeutics0.6245 of 5 stars$31.22+0.8%$35.40+13.4%N/A$858.58MN/A0.00N/APositive News Related Companies and Tools Related Companies BioCryst Pharmaceuticals Alternatives Novavax Alternatives Immunocore Alternatives Mesoblast Alternatives bluebird bio Alternatives Vir Biotechnology Alternatives Adaptive Biotechnologies Alternatives Poseida Therapeutics Alternatives Immatics Alternatives LENZ Therapeutics Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NYSE:PRME) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredPlease don’t take this warning lightly…Something huge is about to hit the stock market. Wall St. legend Louis Navellier calls it: "The most signif...InvestorPlace | Sponsored“The Last Retirement Stock You’ll Ever Need”We've just released a critical trade alert about a groundbreaking AI investment opportunity. So, I wanted t...Behind the Markets | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Prime Medicine, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Prime Medicine With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
